Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A Chemistry World report published on 21 June 2006 described a molecular imaging agent intended to track tumour growth and said it was about to be trialled in the UK. The accessible excerpt does not name the agent or establish whether the trial took place. That imaging story is separate from HRH, a peptide studied in 2017 as a preclinical inhibitor of angiogenesis—not as an imaging agent.
What the 2006 report established
Katharine Sanderson’s Chemistry World report said: “A molecular imaging agent that can track the progress of tumour growth is about to be trialled in the UK.” The statement records a trial plan as reported at the time, not a confirmed trial or result. The accessible excerpt does not identify the agent, provide a trial record, or report what happened afterward. Chemistry World, 21 June 2006
Tracking angiogenesis is not the same as inhibiting it
Angiogenesis is the formation of new blood vessels. An imaging agent is intended to make a biological process or its progress detectable; an inhibitor is intended to reduce that process. The 2006 report concerns imaging. HRH belongs to a separate line of research: a peptide investigated for anti-angiogenic effects. The available sources do not establish that HRH was the 2006 imaging agent.
| Story | Purpose | What the evidence establishes | Clinical status in the available sources |
|---|---|---|---|
| 2006 Chemistry World report | Molecular imaging intended to track tumour growth | A UK trial was described as imminent; the accessible excerpt does not name the agent or give a trial outcome. | Not established. |
| 2017 HRH study | Investigate a peptide as an angiogenesis inhibitor | Cell and animal-model findings; HRH’s exact biochemical mechanism remains unresolved. | Preclinical research only; human efficacy and availability are not established. |
What the 2017 HRH study found
Researchers screened a 12-amino-acid phage-display library against a VEGFR-Fc fusion protein and identified the peptide sequence HRHTKQRHTALH, abbreviated HRH. The study tested it in VEGF-stimulated human umbilical vein endothelial cells, a chick chorioallantoic membrane assay, and two rat corneal neovascularization models. 2017 study in PLOS ONE
#1 Best Overall
- Used Book in Good Condition
- In cell experiments, the authors reported reduced VEGF-stimulated endothelial-cell proliferation.
- In the chick assay, they reported reduced angiogenesis.
- In rat cornea models of alkali burn and suture-induced neovascularization, they reported reduced new-vessel formation. Each model reported eight animals per group.
These findings make HRH a preclinical anti-angiogenic lead, not a demonstrated treatment for patients. The animal counts describe the experimental groups; they are not population-level efficacy statistics.
How certain is HRH’s proposed mechanism?
The authors’ epitope-mapping results suggest HRH may compete with VEGF-family ligands at VEGF receptors. They present that as a possible explanation, not a settled mechanism: the precise biochemical action and effects on intracellular pathways still require study. The paper also reports that 95 selected phage clones were randomly picked for peptide sequence identification after the final panning round; this is a screening-method detail, not a clinical result.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What remains unknown
The key gap in the 2006 story is the identity and later status of its imaging agent. The accessible report excerpt does not say whether the planned UK trial occurred, so the existence of a plan should not be read as evidence of a completed trial, a positive result, or a product available to patients. The separate HRH paper supplies no basis for filling in those missing details.
Recommended Free Tools
Quick Recap
Rank #4
Rank #3
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
